Is this the moment we start to see more of the promise of liquid biopsies?
A common theme across this morning’s #NSCLC presentations at #ESMO26 is early ctDNA clearance, sometimes within just 3–4 weeks.
Could this mean more routine testing and better treatment decisions? #LCSM
11 浏览 · 0 赞 · 0 转发 · 0 回复
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgFirst-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.orgCharacterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: Circulating tumor DNA (ctDNA) analyses from the CROWN study
https://esmocongress.esmo.orgOverall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.orgPhase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: Updated results
https://esmocongress.esmo.orgFirst-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Yvonne Diaz · x.com